Avistone Biotechnology Co., Ltd.

This early-stage study tests a new drug called ANS014004 in about 63 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a specif…

This study tests a new drug, ANS02, in about 294 adults with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check safety and find the right dose, while also seeing if the drug can shrink tumors. Participants must have tried other trea…

This early-stage study tests a new drug called ANS03 in people with advanced solid tumors that have specific gene changes (ROS1 or NTRK). The main goals are to check the drug's safety and see if it can shrink tumors. About 96 adults will take part, and the drug is given alone wit…

This study tests a new drug called andamertinib, alone or with chemotherapy, for people with advanced lung cancer that has certain rare gene changes (atypical EGFR mutations). About 40 participants who have not had prior treatment will be randomly assigned to receive the drug, th…